comscoreAromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease

Aromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease

Dr. Jeremy Braybrooke and Rosie Bradley discuss the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen.
Dec 13, 2021
00:00
Download
00:00

At the 2021 San Antonio Breast Cancer Symposium, Rosie Bradley presented the results of a meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.

Listen to the episode to hear Dr. Jeremy Braybrooke and Rosie explain:

  • the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn’t lead to better overall survival

  • the side effects of aromatase inhibitors and tamoxifen

  • how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease

About the guest
 
Jeremy Braybrooke, BSc, BM, FRCP, PhD

Dr. Jeremy Braybrooke is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford.

Rosie Bradley, MSc, BSc

Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.

— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate